Monte Rosa Shares Gain Ahead of Clinical Trial Review
Dow Jones
Yesterday
Shares of Monte Rosa Therapeutics rose after the company said it will host a live conference call and webcast on Thursday at 8 a.m. Eastern to review clinical results from a recent study.
The stock climbed 20%, to $14.32, in premarket trading Thursday. Through Wednesday's close, shares are down 22% year to date.
The biotechnology company late Wednesday said it will review clinical results from an early-stage study of its in-development treatment--called MRT-8102, a molecular glue degrader--in patients with elevated risk of cardiovascular disease.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.